Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20732391 | 1.00 | TUBB1 (0.51) | TUBB1AKT1 | |
| SCHEMBL22309301 | 1.00 | TUBB1 (0.51) | TUBB1AKT1 | |
| SCHEMBL20732386 | 1.00 | TUBB1 (0.51) | TUBB1AKT1 | |
| SCHEMBL24410045 | 0.93 | TUBB1 (0.50) | TUBB1AKT1 | |
| SCHEMBL24410030 | 0.93 | TUBB1 (0.50) | TUBB1AKT1 | |
| SCHEMBL20732387 | 0.93 | TUBB1 (0.50) | TUBB1AKT1 | |
| SCHEMBL22308042 | 0.93 | TUBB1 (0.50) | TUBB1AKT1 | |
| SCHEMBL24574707 | 0.93 | TUBB1 (0.52) | TUBB1AKT1 | |
| SCHEMBL22100951 | 0.93 | TUBB1 (0.43) | TUBB1AKT1 | |
| SCHEMBL24409907 | 0.92 | TUBB1 (0.49) | TUBB1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-24 | — | — | US | disclosed |
| US-20220144889-A1 | Hemiasterlin Derivative Having Cysteine Residue | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20200247847-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144889-A1 | Hemiasterlin Derivative Having Cysteine Residue | SHBG, CYP11A1, CYP11B1 | TUBB1 1472/4885AKT1 708/4885 |
| US-11795195-B2 | Antibody-drug conjugates including hemiasterlin derivative | HSD3B2, HSD3B1, HSD11B2 | TUBB1 624/4885AKT1 1702/4885 |
| US-20200247847-A1 | Antibody-Drug Conjugates Including Hemiasterlin Derivative | HSD3B2, HSD3B1, HSD11B2 | TUBB1 624/4885AKT1 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.